Literature DB >> 21187478

Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.

Ulisse Cucchi1, Laura M Gianellini, Anna De Ponti, Francesco Sola, Rachele Alzani, Veronica Patton, Alice Pezzoni, Sonia Troiani, Maria B Saccardo, Simona Rizzi, Maria L Giorgini, Paolo Cappella, Italo Beria, Barbara Valsasina.   

Abstract

Polo-like kinase 1 (PLK1) is the master regulator of mitosis and a target for anticancer therapy. To develop a marker of PLK1 activity in cells and tumour tissues, this study focused on translational controlled tumour protein (TCTP) and identified serine 46 as a site phosphorylated by PLK1 in vitro. Using an antibody raised against phospho-TCTP-Ser46, it was demonstrated that phosphorylation at this site correlates with PLK1 level and kinase activity in cells. Moreover, PLK1 depletion by siRNA or inactivation by specific inhibitors caused a correspondent decrease in phospho-TCTP-Ser46 signal validating this site as a direct marker of PLK1. Using this marker, the study characterized PLK1 inhibitors in cells by setting up a high-content assay and finally immunohistochemical assay suitable for following inhibitor activity in preclinical tumour models and possibly in clinical studies was developed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21187478

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  19 in total

1.  High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas.

Authors:  Pramila Ramani; Rachel Nash; Emile Sowa-Avugrah; Chris Rogers
Journal:  J Neurooncol       Date:  2015-08-29       Impact factor: 4.130

2.  TCTP in development and cancer.

Authors:  Magdalena J Koziol; John B Gurdon
Journal:  Biochem Res Int       Date:  2012-05-09

3.  Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Authors:  Glen J Weiss; Gayle Jameson; Daniel D Von Hoff; Barbara Valsasina; Cristina Davite; Claudia Di Giulio; Francesco Fiorentini; Rachele Alzani; Patrizia Carpinelli; Alessandro Di Sanzo; Arturo Galvani; Antonella Isacchi; Ramesh K Ramanathan
Journal:  Invest New Drugs       Date:  2017-07-20       Impact factor: 3.850

4.  Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells.

Authors:  Maria Lucibello; Sara Adanti; Ester Antelmi; Dario Dezi; Stefania Ciafrè; Maria Luisa Carcangiu; Manuela Zonfrillo; Giuseppe Nicotera; Lorenzo Sica; Filippo De Braud; Pasquale Pierimarchi
Journal:  Oncotarget       Date:  2015-03-10

5.  Identification of translationally controlled tumor protein in promotion of DNA homologous recombination repair in cancer cells by affinity proteomics.

Authors:  Y Li; H Sun; C Zhang; J Liu; H Zhang; F Fan; R A Everley; X Ning; Y Sun; J Hu; J Liu; J Zhang; W Ye; X Qiu; S Dai; B Liu; H Xu; S Fu; S P Gygi; C Zhou
Journal:  Oncogene       Date:  2017-08-28       Impact factor: 9.867

6.  A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer.

Authors:  Lifeng Li; Wenhua Xue; Zhibo Shen; Jie Liu; Min Hu; Zhenyong Cheng; Yuxing Wang; Yulu Chen; Hao Chang; Yingyi Liu; Bin Liu; Jie Zhao
Journal:  Mol Ther Oncolytics       Date:  2020-06-23       Impact factor: 7.200

7.  The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.

Authors:  Alessia Casolaro; Josee Golay; Clara Albanese; Roberta Ceruti; Veronica Patton; Sabrina Cribioli; Alice Pezzoni; Marco Losa; Gemma Texido; Ursula Giussani; Francesco Marchesi; Nadia Amboldi; Barbara Valsasina; Silvia Bungaro; Gianni Cazzaniga; Alessandro Rambaldi; Martino Introna; Enrico Pesenti; Rachele Alzani
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

8.  Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor.

Authors:  Merissa Baxter; Danda Chapagai; Sandra Craig; Cecilia Hurtado; Jessy Varghese; Elmar Nurmemmedov; Michael D Wyatt; Campbell McInnes
Journal:  ChemMedChem       Date:  2020-04-28       Impact factor: 3.540

9.  Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair.

Authors:  Peng Lv; Yue Wang; Jie Ma; Zheng Wang; Jing-Li Li; Christopher S Hong; Zhengping Zhuang; Yi-Xin Zeng
Journal:  Oncotarget       Date:  2014-09-15

10.  Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer.

Authors:  Alfonso Parrilla; Marta Barber; Blanca Majem; Josep Castellví; Juan Morote; José Luis Sánchez; Asunción Pérez-Benavente; Miguel F Segura; Antonio Gil-Moreno; Anna Santamaria
Journal:  Cancers (Basel)       Date:  2020-04-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.